COM:IDEAYABIO
IDEAYA Biosciences, Inc.
- Stock
Last Close
31.98
12/11 20:09
Market Cap
2.82B
Beta: -
Volume Today
272.32K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | -60.65M - | -64.81M 6.86% | 262.15M 504.52% | |||||
average payables | 1.04M - | 1.06M 2.26% | 831K 21.83% | 1.53M 83.69% | 3.19M 108.97% | 5.44M 70.50% | ||
average receivables | 938.50K - | 1.49M 58.76% | 657K 55.91% | 114.50K 82.57% | ||||
book value per share | -1.11 - | -3.44 211.00% | 8.03 333.74% | 8.02 0.17% | 8.55 6.64% | 8.43 1.42% | 10.80 28.06% | |
capex per share | -0.12 - | -0.12 2.79% | -0.11 9.73% | -0.02 81.58% | -0.08 276.10% | -0.08 10.76% | -0.04 50.44% | |
capex to depreciation | -4.49 - | -1.93 57.10% | -1.09 43.63% | -0.36 67.15% | -1.53 329.36% | -1.64 6.91% | -0.59 63.95% | |
capex to operating cash flow | 0.14 - | 0.06 56.98% | 0.03 44.35% | -0.01 125.83% | 0.05 633.27% | 0.04 16.68% | 0.02 47.97% | |
capex to revenue | -0.03 - | -0.09 275.02% | -0.07 28.56% | -0.10 49.79% | ||||
cash per share | 0.92 - | 6.32 583.75% | 7.92 25.35% | 11.47 44.87% | 7.00 38.98% | 8.80 25.75% | 9.13 3.71% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | 35.07 - | 14.41 58.91% | 1.51 89.51% | 0.28 81.42% | ||||
debt to assets | 0.06 - | 0.02 62.39% | 0.01 39.72% | 0.01 33.94% | 0.00 50.72% | |||
debt to equity | 0.07 - | 0.03 49.73% | 0.02 49.32% | 0.01 42.01% | 0.00 53.59% | |||
dividend yield | ||||||||
earnings yield | -0.07 - | -0.22 189.55% | -0.41 90.30% | -0.09 77.27% | -0.06 38.82% | -0.07 27.61% | -0.06 24.16% | |
enterprise value | 153.39M - | 138.85M 9.48% | 66.43M 52.16% | 280.79M 322.67% | 746.50M 165.86% | 687.90M 7.85% | 1.89B 175.10% | |
enterprise value over ebitda | -10.92 - | -3.91 64.21% | -1.50 61.60% | -7.94 429.43% | -14.85 86.93% | -11.01 25.89% | -14.51 31.84% | |
ev to operating cash flow | -12.55 - | -5.03 59.94% | -1.69 66.39% | 5.06 399.60% | -13.38 364.35% | -7.89 41.04% | -16.42 108.13% | |
ev to sales | 14.37 - | 26.72 85.90% | 13.51 49.45% | 80.92 499.15% | ||||
free cash flow per share | -0.98 - | -2.06 109.77% | -3.25 58.01% | 2.22 168.33% | -1.66 174.53% | -2.19 31.93% | -2.04 6.50% | |
free cash flow yield | -0.09 - | -0.18 109.77% | -0.43 135.75% | 0.16 136.61% | -0.07 144.14% | -0.12 71.65% | -0.06 52.25% | |
graham net net | -1.41 - | -3.90 176.80% | -1.12 71.18% | -0.54 52.22% | -5.51 926.84% | -0.65 88.12% | 13.27 2,126.19% | |
graham number | 4.55 - | 13.66 200.08% | 23.58 72.66% | 15.35 34.92% | 16.11 4.96% | 15.84 1.67% | 21.84 37.90% | |
income quality | 1.03 - | 0.80 21.96% | 0.94 16.47% | -1.61 271.67% | 1.12 169.71% | 1.49 32.59% | 1.02 31.37% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -41.63 - | -16.25 - | -6.26 61.46% | |||||
interest debt per share | 0.54 - | 0.31 43.48% | 0.15 52.02% | 0.18 20.32% | 0.42 139.29% | |||
inventory turnover | ||||||||
invested capital | 0.07 - | 0.03 49.73% | 0.02 49.32% | 0.01 42.01% | 0.00 53.59% | |||
market cap | 159.36M - | 159.36M 0% | 93.73M 41.18% | 346.10M 269.27% | 833.37M 140.78% | 753.05M 9.64% | 2.05B 171.77% | |
net current asset value | -19.64M - | -54.82M 179.11% | -12.52M 77.16% | -9.66M 22.81% | -130.35M 1,248.83% | -17.52M 86.56% | 504.41M 2,979.85% | |
net debt to ebitda | 0.42 - | 0.58 35.99% | 0.62 6.83% | 1.85 199.73% | 1.73 6.49% | 1.04 39.68% | 1.18 13.39% | |
net income per share | -0.83 - | -2.41 189.55% | -3.08 27.54% | -1.31 57.57% | -1.35 3.31% | -1.32 1.92% | -1.96 48.50% | |
operating cash flow per share | -0.86 - | -1.94 125.95% | -3.15 62.20% | 2.24 171.32% | -1.58 170.53% | -2.10 32.94% | -2.00 4.76% | |
payables turnover | ||||||||
receivables turnover | 10.41 - | 25.33 143.36% | 241.38 852.87% | 1.30K 438.23% | ||||
research and ddevelopement to revenue | 2.03 - | 2.08 2.44% | 1.76 15.54% | 5.54 215.02% | ||||
return on tangible assets | -0.68 - | -0.36 47.58% | -0.34 4.38% | -0.11 68.20% | -0.12 15.22% | -0.14 13.34% | -0.17 23.15% | |
revenue per share | 0.79 - | 0.79 0.29% | 1.23 55.05% | 0.41 66.92% | ||||
roe | 0.75 - | 0.70 6.90% | -0.38 154.57% | -0.16 57.50% | -0.16 3.13% | -0.16 0.51% | -0.18 15.96% | |
roic | 0.91 - | 0.79 12.90% | -0.36 145.11% | -0.16 56.12% | -0.15 1.40% | -0.16 6.43% | -0.21 30.88% | |
sales general and administrative to revenue | 0.78 - | 0.72 7.66% | 0.47 34.62% | 1.21 157.98% | ||||
shareholders equity per share | -1.11 - | -3.44 211.00% | 8.03 333.74% | 8.02 0.17% | 8.55 6.64% | 8.43 1.42% | 10.80 28.06% | |
stock based compensation to revenue | 0.18 - | 0.29 59.60% | 0.23 22.55% | 0.79 246.27% | ||||
tangible asset value | -15.74M - | -48.95M 211.00% | 621.09M - | |||||
tangible book value per share | -1.11 - | -3.44 211.00% | 10.80 - | |||||
working capital | 11.14M - | 85.25M 665.16% | 93.54M 9.72% | 249.97M 167.22% | 205.84M 17.65% | 338.74M 64.57% | 505.53M 49.24% |
All numbers in (except ratios and percentages)